Raymond James Financial’s Co-Diagnostics CODX Stock Holding History

Raymond James Financial’s Portfolio CODX Stock Details CODX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-250	Closed	-$2.1K	–	5322
2025 Q2	$2.1K	Buy	+250	New	+$2.34K	﹤0.01%	6405

Other funds holding CODX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAG

Private Advisory Group Redmond, Washington $1.52B AUM 41.01% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

KAS

Kestra Advisory Services Austin, Texas $31B AUM 28.39% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Raymond James Financial's CODX Position: Q3 2025 in Review

Raymond James Financial sold out of Co-Diagnostics (CODX) in Q3 2025, closing a stake of 250 shares — an estimated $2.1K sold.

Raymond James Financial first reported a position in CODX in Q2 2025 and held it in 1 quarter. The position peaked at $2.1K in Q2 2025. 33 funds tracked by Wall St. Rank hold CODX as of Q3 2025.

Raymond James Financial reported no remaining Co-Diagnostics position as of Q3 2025 after selling out during the quarter.
Raymond James Financial sold 250 Co-Diagnostics shares in Q3 2025, an estimated $2.1K.
Raymond James Financial first reported a position in Co-Diagnostics in Q2 2025 and held it in 1 quarter.
Raymond James Financial's Co-Diagnostics position peaked at $2.1K in Q2 2025.
33 funds tracked by Wall St. Rank held Co-Diagnostics as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.